Changshan Pharmaceutical: Sodium Heparin Injection is expected to be selected for the twelfth batch of national centralized procurement, with projected sales revenue of 120 million yuan in 2025.

Changshan Pharmaceutical announced that the company will participate in the twelfth batch of the national organized centralized drug procurement bidding, with the product heparin sodium injection expected to be selected for this centralized procurement, available in specifications of 0.2ml: 5000IU and 0.3ml: 7500IU. This product is projected to achieve a sales revenue of 120 million yuan in 2025, accounting for 13.71% of the company's operating revenue for the year 2025. The procurement cycle will be effective from the date of the selection results until December 31, 2029. If a procurement contract is subsequently signed and implemented, it will be beneficial for promoting the sales of the related products.